Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Q3 2019 Amicus Therapeutics Inc Earnings Call Transcript

Nov 11, 2019 / 01:30PM GMT
Release Date Price: $7.81
Operator

Good morning, ladies and gentlemen, and welcome to the Amicus Third Quarter 2019 Results Conference Call Webcast. (Operator Instructions)

As a reminder, this call is being recorded. I would now like to turn the conference over to your host, Ms. Sara Pellegrino, Vice President of Investor Relations. You may begin.

Sara Pellegrino
Amicus Therapeutics, Inc. - VP of IR & Corporate Communications

Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics Third quarter 2019 Financial Results and Corporate Highlights. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; and Daphne Quimi, Chief Financial Officer. Also joining for Q&A are Dr. Jay Barth, Chief Medical Officer; Dr. Hung Do, Chief Science Officer; and Dr. Jeff Castelli, Chief Portfolio Officer and Head of Gene Therapy.

As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot